Biolinq Shine™ Granted De Novo Classification by U.S. FDA for the First Fully Autonomous, Needle-Free Glucose Sensor
On Sept. 25, 2025, Biolinq, a pioneering developer of precision multi-analyte biosensors to improve metabolic health, announced the…
-
-
Gene therapy appears to slow Huntington’s disease progression
On Sept. 24, 2025, a global clinical trial for a new Huntington’s disease treatment has posted positive results,…
-
The tale of the creature with the most chromosomes – 229 Pairs
On Sept. 19, 2025, researchers at the Wellcome Sanger Institute and the Institute of Evolutionary Biology, Barcelona reported…
-
Roche to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH for US $3.5 billion
On Sept. 17, 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio,…
-
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill) delivered 16.6% weight loss in people with obesity in a newly published study
On Sept. 17, 2025, The New England Journal of Medicine published the results from the OASIS 4 phase…
-
New University of Alberta health institute will help research breakthroughs reach patients sooner
On Sept. 15, 2025, the University of Alberta (U of A) announced the Dianne and Irving Kipnes Health…
-
Biotechnology | Disease | FDA | Therapeutics
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
On Sept. 15, 2025, Corstasis Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ENBUMYST™…
-
gene therapy offers hope for genetic hearing loss
On Sept. 14, 2025, scientists from the Gray Faculty of Medical & Health Sciences at Tel Aviv University…
-
UK trial launches to transform Alzheimer’s diagnosis with simple blood test
On Sept. 10, 2025, a major University of London (UCL)-led clinical trial, aiming to transform the diagnosis of…
-
Long-term alcohol use suspends liver cells in limbo, preventing regeneration
On Sept. 10, 2025, researchers at University of Illinois Urbana-Champaign and collaborators at Duke University and the Chan…
-
Novartis to acquire Tourmaline Bio and pipeline for atherosclerotic cardiovascular disease, valued at $1.4 Billion
On Sept. 9, 2025, Novartis announced that it has entered into an agreement to acquire Tourmaline Bio, a…
-
Nearly half of people with diabetes don’t realize they have the disease
On Sept. 8, 2025, the Institute for Health Metrics and Evaluation (IHME) at the University of Washington School…
-
Hope for diabetes: CRISPR-edited cells pump out insulin in a person — and evade immune detection
On Sept. 5, 2025, in a medical first, researchers report that they have implanted CRISPR-edited pancreas cells into…
-
Golden Goose Award Honors Federally Funded Breakthroughs in Cancer Treatments and Disease Diagnostics
On Sept. 3, 2025, The Golden Goose Award, which spotlights obscure, silly sounding or odd fundamental discovery research that…
-
C2N Diagnostics Expands St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease
On Sept. 3, 2025, C2N Diagnostics (C2N), a specialty diagnostics company announce that its early achievements while based…
-
Amgen to Invest $600 Million in New State-of-the-Art Center for Science Innovation at U.S. Headquarters
On Sept. 2, 2025, Amgen announced plans to invest more than $600 million in a new, state-of-the-art center…
-
OMass Therapeutics announces Collaboration and License Agreement for IBD with Genentech Worth $420 Million
On Sept. 2, 2025, OMass Therapeutics announces an exclusive collaboration and license agreement with Genentech, a member of…
-
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
On Sept. 2, 2025, Arrowhead Pharmaceuticals announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s…
-
new resource, MacroMap, provides a rich dataset that researchers can use to explore genetic mechanisms behind complex diseases
On Aug. 27, 2025, scientists from the Wellcome Sanger Institute reveal insights into how our genes influence the…
-
Georgia State Scientists Revive Ancient Gene to Target Gout, Fatty Liver Disease
On Aug. 26, 2025, scientists at Georgia State University (GSU) announced a study published in Scientific Reports that…
-
AbbVie to Acquire Gilgamesh Pharma’s Investigational Therapy for Major Depressive Disorder for $1.2 Billion
On Aug. 25, 2025, AbbVie and Gilgamesh Pharmaceuticals announced a definitive agreement under which AbbVie will acquire Gilgamesh’s…
-
In a first, pig lung survives and functions—briefly—in a person
On Aug. 25, 2025, in a small step forward for the long-struggling field of xenotransplantation, surgeons in China…
-
C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older
On Aug. 25, 2025, C2N Diagnostics (C2N) announced lower age limit addresses increasing calls from clinicians seeking access…
-
Mayo Clinic research set to launch aboard NASA mission to International Space Station to explore new therapies for bone loss
On Aug. 22, 2025, the Mayo Clinic announced that its pioneering exploration of stem cell-based therapies for bone…
-
MSDH Declares Public Health Emergency on Infant Mortality
On Aug. 21, 2025, the Mississippi State Department of Health (MSDH) declared a public health emergency after reporting…
-
New Method Advances Reliability of Ai with Applications in Medical Diagnostics
On Aug. 20, 2025, two studies led by Johns Hopkins Kimmel Cancer Center, Ludwig Center, and Johns Hopkins Whiting School of…
-
Biggest shake-up in type 2 diabetes care in a decade announced
On Aug. 20, 2025, the National Institute for Health and Care Excellence (NICE) announced that millions of people…
-
Biotechnology | Disease | FDA | Medicine | Therapeutics
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients
On Aug. 18, 2025, Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type…
-
Biotechnology | Disease | FDA | Therapeutics
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
On Aug. 15, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved a…
-
Precigen Announces FDA Approval of PAPZIMEOS, the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
On Aug. 15, 2025, Precigen announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba)…
